健存肾单位负荷过重 出球小动脉阻力入球小动脉阻力 单个健存肾单位高灌注、高压力、高滤过 实用内科学第九期P1523 HowtouseACEIinrenalfailure 肾小球内高压的后果 高血压肾实质减少糖尿病 肾小球内高压 血管内皮内皮由来因子启动血栓形成系膜细胞吞噬基质增生小球硬化上皮细胞大分子物质滤过、蛋白尿 ...
Renal Failure 研究:百令胶囊联合西药可有效提高免疫 最近,中南大学湘雅二医院孙林教授等对使用百令胶囊治疗的患者样本进行分析,结果发表在Renal Failure上。该项研究使用冬虫夏草联合血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体阻阻剂(ARB)与单独ACEI/ ARB治疗糖尿病肾病的一项联合分析。 研究方法 研究纳入了861名患...
肾素血管紧张素系统(renal Angiotensin system,RAS)与肾小管周围分泌EPO的毛细血管内皮细胞相联系,激活这个系统将增加EPO的生成,使用ACEI抑制血管紧张素Ⅱ(AngiotensinⅡ,AngⅡ)的产生可以使EPO的生成减少,降低周围循环中的EPO水平,加重贫血,ACEI的这个特征已经很好地用于肾移植术后的红细胞增多症(post-transplant erythroc...
25、残留肾功能的重要性 * ACEI应当使用,但需密切监测血钾应当使用,但需密切监测血钾 ACEI-在糖尿病肾病中的应 用 The current practice of avoiding ACE inhibitors in severe renal failure, to prevent further renal impairment and hyperkalaemia, is no longer justified. (Ruggenenti P, Lancet 1999,354...
文献索引:Wilfried Mullens, Pieter Martens, Jeffrey M. Testani, et al. Renal effects of guideline directed medical therapies in heart failure – a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022 Mar 3. doi: 10.1002/ejhf.247...
1、Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.Sunil Bhandari, Natalie Ives, Elizabeth A Brettell et al. Nephrol Dial Trans...
[16]Shen J, Huang Y M, Song X N, et al. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. Journal of the renin-angiotensin-aldosterone system: JRAAS, 2016, 17(3). ...
Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long‐Term Registry: bridging between EMA/FDA label, the PARADIGM‐HF trial... Aims To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for LCZ696 based on...
ACEI在慢性心力衰竭中的应用.ppt,ACEI副作用:肾功能恶化(3) 血清肌酐水平轻度增高不是停用ACEI 的指征,特别是如果尿素或肌酐清除率的下降并未引起症状、尿钠排泄量并未减少(用或不用利尿剂时) 动脉灌注压维持适当情况下,血清肌酐增高1倍以上时可考虑减少ACEI 剂量,或
[7] Shen J, Huang YM, Song XN, et al.Protection against death and renal failure by renin-angiotensin systemblockers in patients with diabetes and kidney disease. Journal of the renin-angiotensin-aldosterone system: JRAAS, 2016, 17(3). ...